Global Information
회사소개 | 문의 | 비교리스트

세계의 비침습적 출생전 검사(NIPT) 시장(2020-2031년) : 방법, 검사, 플랫폼, 최종사용자, 용도, 국가별

Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Test, Platform, End User, Application and Country Analysis - Analysis and Forecast, 2020-2031

리서치사 BIS Research Inc.
발행일 2021년 12월 상품코드 1044838
페이지 정보 영문 배송안내 1-2일 (영업일 기준)
가격
US $ 5,250 ₩ 6,689,000 PDF (1-3 User License)
US $ 8,100 ₩ 10,321,000 PDF and Excel (Global License)


세계의 비침습적 출생전 검사(NIPT) 시장(2020-2031년) : 방법, 검사, 플랫폼, 최종사용자, 용도, 국가별 Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Test, Platform, End User, Application and Country Analysis - Analysis and Forecast, 2020-2031
발행일 : 2021년 12월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 비침습적 출생전 검사(NIPT) 시장 규모는 2031년에 126억 1,000만 달러 규모로 성장할 것으로 예측됩니다.

NIPT 시장의 성장은 세계의 상환 정책과 보험 적용의 증가에 기인하고 있습니다. 또한 업계의 수요에 부응하기 위해 의료기관이 게놈 배열 해석에 거액의 투자를 계속하고 있는 것 및 유전성 질환의 발생률이 높아지고 있는 것도 세계 NIPT 시장의 성장을 촉진하는 요인입니다.

세계의 비침습적 출생전 검사(NIPT) 시장을 조사했으며, 시장 및 제품의 개요, 시장 영향요인 분석, 법규제·상환 프레임워크, 시장 규모의 추이·예측, 검사·방법·플랫폼·용도·최종사용자·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 제품의 정의

제2장 조사 범위

제3장 조사 방법

제4장 시장 개요

  • NIPT의 채택에 영향을 미치는 요인
  • NIPT 어프로치
  • NIPT의 다양한 방법
  • NIPT에 관련된 이점과 리스크
  • 염색체 이수성
  • 주요 염색체 이수성의 특징과 발생률
  • 기술의 진보
  • NIPT 시장의 세계 경제적 전망
  • 세계의 발자국

제5장 시장 역학

  • 개요
  • 영향 분석
  • 시장 촉진요인
  • 시장 억제요인
  • 시장 기회

제6장 업계 인사이트

  • 규제 프레임워크
  • CLIA(Clinical Laboratory Improvement Amendments) 프로그램
  • 비용과 액세스
  • 상환 시나리오
  • 자금조달 시나리오
  • 공급망
  • COVID-19의 영향

제7장 경쟁 구도

  • 개요
  • 주요 개발·전략
  • 기업별 시장 점유율 분석
  • 성장 점유율 분석

제8장 세계의 NIPT 시장 : 검사별

  • 개요
  • Panorama·Vistara
  • MaterniT GENOME·MaterniT 21 PLUS·informaSeq
  • Verifi·VerifiPlus
  • Harmony Test
  • NIFTY Test·NIFTY-Test Pro
  • QNatal Advanced
  • PrenaTest·GeneSafe·PrenatalSAFE
  • Bambni Test
  • IONA·Sage
  • 기타

제9장 세계의 NIPT 시장 : 방법별

  • 개요
  • cfDNA
  • FCMB

제10장 세계의 NIPT 시장 : 플랫폼별

  • 개요
  • 차세대 시퀀스
  • PCR
  • 기타

제11장 세계의 NIPT 시장 : 용도별

  • 개요
  • 트리소미 검출
  • 미세결실 검출
  • 성염색체 이수성 검출
  • 기타

제12장 세계의 NIPT 시장 : 최종사용자별

  • 개요
  • 병원
  • 클리닉
  • 진단 랩
  • 기타

제13장 세계의 NIPT 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 기타 지역

제14장 기업 개요

  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • BGI
  • CENTOGENE N.V.
  • Laboratory Corporation of America Holdings
  • MedGenome Inc.
  • Annoroad Gene Technology
  • Natera, Inc.
  • Yourgene Health PLC
  • Next Biosciences
  • Eurofins Scientific
KSA 22.01.20

List of Figures

  • Figure 1: Global NIPT Market (by Region), by Revenue, $Million, 2020-2031
  • Figure 2: Global NIPT Market (by Region), by Volume, Thousand Units, 2020 and 2031
  • Figure 3: Impact of Market Drivers and Market Restraints
  • Figure 4: Share of Key Developments and Strategies, January 2017-October 2021
  • Figure 5: Market Statistics
  • Figure 6: Global NIPT Market Share (by Test), 2020-2031
  • Figure 7: Global NIPT Market Share (by Method), 2020-2031
  • Figure 8: Global NIPT Market Share (by Platform), 2020-2031
  • Figure 9: Global NIPT Market Share (by Application), 2020-2031
  • Figure 10: Global NIPT Market Share (by End User), 2020-2031
  • Figure 11: Global NIPT Market Segmentation
  • Figure 12: Global NIPT Market Methodology
  • Figure 13: Primary Research Methodology
  • Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 15: Top-Down Approach (Segment-Wise Analysis)
  • Figure 16: Prenatal Testing Timeline During Pregnancy
  • Figure 17: Different Indications for NIPT
  • Figure 18: NIPT Approach
  • Figure 19: Benefits and Risks of NIPT
  • Figure 20: Features of the Major Chromosome Aneuploidies
  • Figure 21: Incidence Rate of Major Chromosome Aneuploidies
  • Figure 22: Ecosystem Players of Global Non-Invasive Prenatal Testing Market
  • Figure 23: Global NIPT Market, by Revenue, $Million, 2020-2031
  • Figure 24: Global NIPT Market, by Volume, Thousand Units, 2020-2031
  • Figure 25: Number of Tests Processed by Natera, Inc., 2018-2020
  • Figure 26: NGS-Based Screening Technologies by Major Companies
  • Figure 27: Reimbursement Policies Covering Prenatal Testing in the Europe Market
  • Figure 28: Births with Down's Syndrome per 100,000 Live Births in Europe Region (2011-2018)
  • Figure 29: Examples of Investment and Funding by Key Companies
  • Figure 30: Classification of Tests in CLIA Program
  • Figure 31: Cost Range of NIPT in Major Countries
  • Figure 32: Reimbursement Scenario in Major Countries of the Global NIPT Market
  • Figure 33: Supply Chain of Global NIPT Market
  • Figure 34: Pre-COVID and Post-COVID Growth Trend of the Global NIPT Market, 2020-2025
  • Figure 35: Competitive Landscape (January 2017-October 2021)
  • Figure 36: Share of Key Developments and Strategies, January 2017-October 2021
  • Figure 37: New Offerings (by Company), January 2017-October 2021
  • Figure 38: Partnerships and Alliances (by Company), January 2017-October 2021
  • Figure 39: Product Approvals (by Company), January 2017-October 2021
  • Figure 40: Business Expansions (by Company), January 2017-October 2021
  • Figure 41: Merger and Acquisition Activities (by Company), January 2017-October 2021
  • Figure 42: Market Share Analysis of Global NIPT Market, 2020
  • Figure 43: Growth Share Matrix for NIPT Market (by Platform), 2019-2020
  • Figure 44: Global NIPT Segmentation (by Test)
  • Figure 45: Global NIPT Market (by Test), by Revenue, $Million, 2020-2031
  • Figure 46: Global NIPT Market for Panorama and Vistara (by Revenue), $Million, 2020-2031
  • Figure 47: Global NIPT Market for MaterniT GENOME, MaterniT 21 PLUS, and informaSeq, (by Revenue), $Million, 2020-2031
  • Figure 48: Global NIPT Market for Verifi and Verifi Plus Prenatal Tests (by Revenue), $Million, 2020-2031
  • Figure 49: Global NIPT Market for Harmony Test (by Revenue), $Million, 2020-2031
  • Figure 50: Global NIPT Market for NIFTY Test and NIFTY Test Pro (by Revenue), $Million, 2020-2031
  • Figure 51: Global NIPT Market for QNatal Advanced (by Revenue), $Million, 2020-2031
  • Figure 52: Global NIPT Market for PrenaTest, GeneSafe, and PrenatalSAFE (by Revenue), $Million, 2020-2031
  • Figure 53: Global NIPT Market for Bambni Test (by Revenue), $Million, 2020-2031
  • Figure 54: Global NIPT Market for IONA and Sage (by Revenue), $Million, 2020-2031
  • Figure 55: Global NIPT Market for Other Tests (by Revenue), $Million, 2020-2031
  • Figure 56: Global NIPT Segmentation (by Method)
  • Figure 57: Global NIPT Market (by Method), by Revenue, $Million, 2020-2031
  • Figure 58: Global NIPT Market (by Method), by Volume, Thousand Units, 2020-2031
  • Figure 59: Global NIPT Market for cfDNA (by Revenue), $Million, 2020-2031
  • Figure 60: Global NIPT Market for cfDNA (by Volume), Thousand Units, 2020-2031
  • Figure 61: Global NIPT Market for FCMB (by Revenue), $Million, 2020-2031
  • Figure 62: Global NIPT Market for FCMB (by Volume), Thousand Units, 2020-2031
  • Figure 63: Global NIPT Segmentation (by Platform)
  • Figure 64: Global NIPT Market (by Platform), by Revenue, $Million, 2020-2031
  • Figure 65: Global NIPT Market (by Platform), by Volume, Thousand Units, 2020-2031
  • Figure 66: Global NIPT Market for NGS (by Revenue), $Million, 2020-2031
  • Figure 67: Global NIPT Market for NGS (by Volume), Thousand Units, 2020-2031
  • Figure 68: Global NIPT Market for PCR (by Revenue), $Million, 2020-2031
  • Figure 69: Global NIPT Market for PCR (by Volume), Thousand Units, 2020-2031
  • Figure 70: Global NIPT Market for Other Platforms (by Revenue), $Million, 2020-2031
  • Figure 71: Global NIPT Market for Other Platforms (by Volume), Thousand Units, 2020-2031
  • Figure 72: Global NIPT Segmentation (by Application)
  • Figure 73: Global NIPT Market (by Application), by Revenue, $Million, 2020-2031
  • Figure 74: Global NIPT Market (by Application), by Volume, Thousand Units, 2020-2031
  • Figure 75: Global NIPT Market for Trisomy Detection (by Revenue), $Million, 2020-2031
  • Figure 76: Global NIPT Market for Trisomy Detection (by Volume), Thousand Units, 2020-2031
  • Figure 77: Global NIPT Market for Microdeletion Detection (by Revenue), $Million, 2020-2031
  • Figure 78: Global NIPT Market for Microdeletion Detection (by Volume), Thousand Units, 2020-2031
  • Figure 79: Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Revenue), $Million, 2020-2031
  • Figure 80: Global NIPT Market for Sex Chromosome Aneuploidy Detection (by Volume), Thousand Units, 2020-2031
  • Figure 81: Global NIPT Market for Others (by Revenue), $Million, 2020-2031
  • Figure 82: Global NIPT Market for Others (by Volume), Thousand Units, 2020-2031
  • Figure 83: Global NIPT Segmentation (by End User)
  • Figure 84: Global NIPT Market (by End User), by Revenue, $Million, 2020 and 2031
  • Figure 85: Global NIPT Market (by End User), by Volume, Thousand Units, 2020 and 2031
  • Figure 86: Global NIPT Market for Hospital (by Revenue), $Million, 2020 and 2031
  • Figure 87: Global NIPT Market for Hospital (by Volume), Thousand Units, 2020 and 2031
  • Figure 88: Global NIPT Market for Clinics (by Revenue), $Million, 2020 and 2031
  • Figure 89: Global NIPT Market for Clinics (by Volume), Thousand Units, 2020 and 2031
  • Figure 90: Global NIPT Market for Diagnostic Labs (by Revenue), $Million, 2020 and 2031
  • Figure 91: Global NIPT Market for Diagnostic Labs (by Volume), Thousand Units, 2020 and 2031
  • Figure 92: Global NIPT Market for Others (by Revenue), $Million, 2020 and 2031
  • Figure 93: Global NIPT Market for Others (by Volume), Thousand Units, 2020 and 2031
  • Figure 94: Global NIPT Market (by Region)
  • Figure 95: Global NIPT Market (by Region), by Revenue, $Million, 2020-2031
  • Figure 96: Global NIPT Market (by Region), $Million, 2020-2031
  • Figure 97: Global NIPT Market (by Region), by Volume, Thousand Units, 2020 and 2031
  • Figure 98: Global NIPT Market (by Region), Thousand Units, 2020-2031
  • Figure 99: North America: NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 100: North America: NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 101: North America: Market Dynamics
  • Figure 102: North America: NIPT Market Share (by Country), by Revenue, $Million, 2020 and 2031
  • Figure 103: North America: NIPT Market Share (by Country), by Volume, Thousand Units, 2020 and 2031
  • Figure 104: Pricing Analysis by Leading NIPT Test, 2020
  • Figure 105: U.S. NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 106: U.S. NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 107: Organizations Offering NIPT Test in United States
  • Figure 108: Market Share Analysis of U.S. NIPT Market, $Million, 2020
  • Figure 109: Pricing Analysis by Leading NIPT Test in U.S., 2020
  • Figure 110: Canada NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 111: Canada NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 112: Organizations Offering NIPT Test in Canada
  • Figure 113: Market Share Analysis of Canada NIPT Market, $Million, 2020
  • Figure 114: Pricing Analysis by Leading NIPT Test in Canada, 2020
  • Figure 115: Europe: NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 116: Europe NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 117: Europe Market Dynamics
  • Figure 118: Europe: NIPT Market Share (by Country), by Revenue, $Million 2020 and 2031
  • Figure 119: Europe: NIPT Market Share (by Country), by Volume, Thousand Units 2020 and 2031
  • Figure 120: Pricing Analysis by Leading NIPT Test in EU-5, 2020
  • Figure 121: Germany NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 122: Germany NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 123: Organizations Offering NIPT Test in Germany
  • Figure 124: Market Share Analysis of Germany NIPT Market, $Million, 2019-2020
  • Figure 125: France NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 126: France NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 127: Organizations Offering NIPT Test in France
  • Figure 128: Market Share Analysis of France NIPT Market, $Million, 2019-2020
  • Figure 129: Italy NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 130: Italy NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 131: Organizations Offering NIPT Test in Italy
  • Figure 132: Market Share Analysis of Italy NIPT Market, $Million, 2019-2020
  • Figure 133: U.K. NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 134: U.K. NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 135: Organizations Offering NIPT Test in the U.K.
  • Figure 136: Market Share Analysis of U.K. NIPT Market, $Million, 2019-2020
  • Figure 137: Spain NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 138: Spain NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 139: Organizations Offering NIPT Test in the Spain
  • Figure 140: Market Share Analysis of Spain NIPT Market, $Million, 2019-2020
  • Figure 141: Russia NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 142: Russia NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 143: Organizations Offering NIPT Test in the Russia
  • Figure 144: Market Share Analysis of Russia NIPT Market, $Million, 2019-2020
  • Figure 145: Poland NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 146: Poland NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 147: Organizations Offering NIPT Test in Poland
  • Figure 148: Market Share Analysis of Poland NIPT Market, $Million, 2019-2020
  • Figure 149: Netherlands NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 150: Netherlands NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 151: Organizations Offering NIPT Test in Netherlands
  • Figure 152: Market Share Analysis of Netherlands NIPT Market, $Million, 2019-2020
  • Figure 153: Belgium NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 154: Belgium NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 155: Organizations Offering NIPT Test in Belgium
  • Figure 156: Market Share Analysis of Belgium NIPT Market, $Million, 2019-2020
  • Figure 157: Switzerland NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 158: Switzerland NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 159: Organizations Offering NIPT Test in Switzerland
  • Figure 160: Market Share Analysis of Switzerland NIPT Market, $Million, 2019-2020
  • Figure 161: Denmark NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 162: Denmark NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 163: Organizations Offering NIPT Test in Denmark
  • Figure 164: Market Share Analysis of Denmark NIPT Market, $Million, 2019-2020
  • Figure 165: Sweden NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 166: Sweden NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 167: Organizations Offering NIPT Test in Sweden
  • Figure 168: Market Share Analysis of Sweden NIPT Market, $Million, 2019-2020
  • Figure 169: Rest-of-Europe NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 170: Rest-of-Europe NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 171: APAC NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 172: APAC: NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 173: APAC Market Dynamics
  • Figure 174: APAC NIPT Market Share (by Country), by Revenue, 2020 and 2031
  • Figure 175: APAC NIPT Market Share (by Country), by Volume, 2020 and 2031
  • Figure 176: China NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 177: China NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 178: Japan NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 179: Japan NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 180: India NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 181: India NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 182: Australia NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 183: Australia NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 184: South Korea NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 185: South Korea NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 186: Hong Kong NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 187: Hong Kong NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 188: Malaysia NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 189: Malaysia NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 190: Indonesia NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 191: Indonesia NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 192: Vietnam NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 193: Vietnam NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 194: Thailand NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 195: Thailand NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 196: Philippines NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 197: Philippines NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 198: Rest-of-APAC NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 199: Rest-of-APAC NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 200: LATAM NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 201: LATAM NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 202: RoW NIPT Market (by Revenue), $Million, 2020-2031
  • Figure 203: RoW NIPT Market (by Volume), Thousand Units, 2020-2031
  • Figure 204: Shares of Key Company Profiles
  • Figure 205: Agilent Technologies, Inc.: Product Portfolio for Global NIPT Market
  • Figure 206: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 207: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 208: Agilent Technologies, Inc.: Revenue (By Region), $Millions, 2018-2020
  • Figure 209: Agilent Technologies, Inc.: R&D Expenditure, $Millions, 2018-2019
  • Figure 210: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 211: Hoffmann-La Roche Ltd: Product Portfolio for Global NIPT Market
  • Figure 212: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2018-2020
  • Figure 213: F. Hoffmann-La Roche Ltd: Revenue (by Segment), Billions, 2018-2020
  • Figure 214: F. Hoffmann-La Roche Ltd: Revenue (by Region), Billions, 2018-2020
  • Figure 215: F. Hoffmann-La Roche Ltd: R&D Expenditure, Billions, 2018-2020
  • Figure 216: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 217: PerkinElmer, Inc.: Product Portfolio for Global NIPT Market
  • Figure 218: PerkinElmer, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 219: PerkinElmer, Inc.: Revenue (by Segment), Millions, 2018-2020
  • Figure 220: PerkinElmer, Inc.: Revenue (by Region), Millions, 2018-2020
  • Figure 221: PerkinElmer, Inc.: R&D Expenditure, Millions, 2018-2020
  • Figure 222: PerkinElmer, Inc.: SWOT Analysis
  • Figure 223: Quest Diagnostics Incorporated's Product Portfolio for Global NIPT Market
  • Figure 224: Quest Diagnostics Incorporated.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 225: Quest Diagnostics Incorporated, Revenue (by Segment), Millions, 2018-2020
  • Figure 226: Quest Diagnostics Incorporated, SWOT Analysis
  • Figure 227: Illumina, Inc.: Product Portfolio for Global NIPT Market
  • Figure 228: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 229: Illumina, Inc.: Revenue (by Segment), Millions, 2018-2020
  • Figure 230: Illumina, Inc.: Revenue (by Region), Millions, 2018-2020
  • Figure 231: Illumina, Inc.: R&D Expenditure, Millions, 2018-2020
  • Figure 232: Illumina, Inc.: SWOT Analysis
  • Figure 233: Myriad Genetics, Inc.: Product Portfolio for Global NIPT Market
  • Figure 234: Myriad Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 235: Myriad Genetics, Inc.: Revenue (by Product/Service), Millions, 2018-2020
  • Figure 236: Myriad Genetics, Inc.: R&D Expenditure, Millions, 2018-2020
  • Figure 237: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 238: BGI: Product Portfolio for Global NIPT Market
  • Figure 239: BGI: SWOT Analysis
  • Figure 240: CENTOGENE N.V.: Product Portfolio for Global NIPT Market
  • Figure 241: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 242: CENTOGENE N.V.: Revenue (by Segment), Millions, 2018-2020
  • Figure 243: CENTOGENE N.V.: Revenue (by Region), Millions, 2018-2020
  • Figure 244: CENTOGENE N.V.: R&D Expenditure, Millions, 2018-2020
  • Figure 245: CENTOGENE N.V.: SWOT Analysis
  • Figure 246: Laboratory Corporation of America Holdings: Product Portfolio for Global NIPT Market
  • Figure 247: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 248: Laboratory Corporation of America Holdings: Revenue (by Segment), Millions, 2018-2020
  • Figure 249: Laboratory Corporation of America Holdings: Revenue (By Region), Millions, 2018-2020
  • Figure 250: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 251: MedGenome Inc.: Product Portfolio for Global NIPT Market
  • Figure 252: MedGenome Inc.: SWOT Analysis
  • Figure 253: Annoroad Gene Technology: Product Portfolio for Global NIPT Market
  • Figure 254: Annoroad Gene Technology: SWOT Analysis
  • Figure 255: Natera, Inc.: Product Portfolio for Global NIPT Market
  • Figure 256: Natera, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 257: Natera, Inc.: Revenue (by Region), Millions, 2018-2020
  • Figure 258: Natera, Inc.: R&D Expenditure, Millions, 2018-2020
  • Figure 259: Natera, Inc.: SWOT Analysis
  • Figure 260: Yourgene Health PLC: Product Portfolio for Global NIPT Market
  • Figure 261: Yourgene Health PLC: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 262: Yourgene Health PLC: Revenue (by Region), Millions, 2018-2020
  • Figure 263: Yourgene Health PLC: SWOT Analysis
  • Figure 264: Next Biosciences: Product Portfolio for Global NIPT Market
  • Figure 265: Next Biosciences SWOT Analysis
  • Figure 266: Eurofins Scientific: Product Portfolio for Global NIPT Market
  • Figure 267: Eurofins Scientific Overall Financials/Revenue, $Million, 2018-2020
  • Figure 268: Eurofins Scientific Revenue (by Region), Millions, 2018-2020
  • Figure 269: Eurofins Scientific: SWOT Analysis

List of Tables

  • Table 1: Major Chromosomal Aneuploidies
  • Table 2: Technological Approach for NIPT
  • Table 3: Impact Analysis of Market Drivers
  • Table 4: Impact Analysis of Market Restraints
  • Table 5: Risk of Chromosomal Abnormality w.r.t Maternal Age
  • Table 6: Chromosome (Gene) Defects Prevalence Per Year in the U.S.
  • Table 7: List of Regulatory Authorities Involved in CLIA Program
  • Table 8: Major Funding Activities (January 2017-June 2020)
  • Table 9: Key Companies Offering cfDNA-Based NIPT Solution
  • Table 10: Key Companies Offering FCMB-Based NIPT Solution
  • Table 11: Key Companies Offering NGS-Based NIPT Solution
  • Table 12: Key Companies Offering PCR-Based NIPT Solution
  • Table 13: Key Companies Offering Other Platform-Based NIPT Solution
  • Table 14: Key Companies Offering NIPT Solution for Trisomy Detection
  • Table 15: Key Companies Offering NIPT Solution for Microdeletion Detection
  • Table 16: Key Companies Offering NIPT Solution for SCA Detection

“Global Non-Invasive Prenatal Testing (NIPT) Market to Reach $12.61 Billion by 2031.”

Market Report Coverage - Non-Invasive Prenatal Testing (NIPT)

Market Segmentation

  • By Test - Panorama and Vistara; MaterniT GENOME, MaterniT 21 PLUS, informaSeq, Verifi and Verifi Plus Prenatal Tests; Harmony Test; NIFTY Test and NIFTY Test Pro; QNatal Advanced; PrenaTest, GeneSafe, and PrenatalSAFE; Bambni Test; IONA and Sage; and Others
  • By Platform - PCR, Next-Generation Sequencing, and Others
  • By Method - cfDNA and FCMB
  • By End User - Hospitals, Clinics, Diagnostic Labs, and Others
  • By Application - Trisomy Detection, Microdeletion Detection, Sex Chromosome Aneuploidy Detection, Others

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Switzerland, Spain, Netherlands, Belgium, Russia, Poland, Denmark, Sweden, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, South Korea, Hong Kong, Malaysia, Indonesia, Vietnam, Thailand, Philippines, and Rest-of-Asia-Pacific
  • Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Increased Emphasis on Early Detection and Prevention
  • Availability of Advanced Screening Technologies
  • Increasing Consumer Demand
  • Shifting of Reimbursement Policies Toward More Genetics Coverage
  • High Incidence Rate of Down's Syndrome
  • Rising Average Maternal Age
  • Increasing Prevalence of Genetic and Congenital Disorders

Market Challenges

  • Stringent Regulatory Guidelines and Ethical Hurdles
  • Limitations of NIPT
  • Lack of Awareness Among Consumers
  • Alternative Screening and Testing Methods

Market Opportunities

  • Capitalizing on the Potential Presented by the Emerging Markets in Asia
  • Availability of Direct-to-Consumer Tests
  • Focus on Pre-Implantation Genetic Diagnosis

Key Companies Profiled

Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, PerkinElmer, Inc., Quest Diagnostics Incorporated, Illumina, Inc., Myriad Genetics, Inc., BGI, CENTOGENE N.V., Laboratory Corporation of America Holdings, MedGenome Inc., Annoroad Gene Technology, Natera, Inc., Yourgene Health PLC, Next Biosciences, Eurofins Scientific.

Key Questions Answered in this Report:

  • What is the importance of NIPT, and what are the different NIPT products/services available in the market? What are the different methods of NIPT, and what are the benefits and risks associated with it?
  • What are the major technological advancements witnessed by the global NIPT market in the past four years, and what is the future scope of the market? What are the key trends of the global NIPT market as per the year 2020, and how is the market evolving currently?
  • What was the market size of the global NIPT market in 2020, and what is the market size anticipated to be in 2031? What is the expected growth rate of the global NIPT market during the period 2021-2031?
  • What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
  • What are the major drivers, challenges, and opportunities of the global NIPT market?
  • Who are the major key players of the global NIPT market? How much market share does each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future, and why?
  • What is the regulatory scenario of the global NIPT market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of NIPT products?
  • What is the average NIPT cost in different countries? What is the reimbursement scenario of the global NIPT market, and what is the reimbursement rate in different countries of the world, including countries of North America, Latin America, Asia-Pacific, Europe, and the Middle East and Africa?
  • What is the funding scenario of the market with respect to institutional and academic funding? What is the patent landscape of the market, and which companies stand out for registering the greatest number of patents?
  • What are the key developmental strategies implemented by the key players of the global NIPT market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What are the different NIPT tests available in the market, and which test type dominates the market in 2020 and 2031 in terms of value and volume?
  • What is the global market size (by value and volume) of different types of products of the global NIPT market in 2020? What are the key trends of the market with respect to different kits, assays, and which product is expected to dominate the market in 2031?
  • What are the different platforms supported by NIPT products? Which technology type dominated the market in 2020 and is expected to dominate in 2031 (by value and volume)?
  • What are the different applications associated with NIPT? What was the contribution of each of the application areas in the global NIPT market for the period between 2021 and 2031 (by value and volume)?
  • What is the global NIPT market size (by value and volume) based on different methods? Which method is currently leading the market and why? Which method is expected to lead the market during the forecast period?
  • Who are the different end users of the global NIPT market (by value and volume)? Which end-user type is the major contributor of revenue in the market?

Market Overview

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. The growth in the market is attributed to the increasing reimbursement policies and insurance coverage across the globe. Further, the continued significant investments for genome sequencing by healthcare companies to meet the industry demand and the growing incidence of genetic disorders are the prominent factors propelling the growth of the global NIPT market.

Advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.

Our healthcare experts have found global NIPT market as one of the most rapidly evolving markets amongst the other prenatal testing industries. The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well. Also, aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion

Within the research report, the market has been segmented into 'platforms,' 'tests,' 'methods,' 'applications,' 'end-user', and 'regions.'. Each of these segments covers the inclination of the market revenue, underlying patterns, snapshot of the market over the projected years, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The NIPT market is currently at a blooming phase, with the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering wide range of NIPT products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Table of Contents

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Work

  • 2.1 Overview: Report Scope
  • 2.2 Segmentation of the Global NIPT Market
  • 2.3 Assumptions and Limitations
  • 2.4 Key Questions Answered in the Report
  • 2.5 Base Year and Forecast Period

3 Research Methodology

  • 3.1 Overview: Report Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Introduction
  • 4.2 Factors Influencing the Adoption of NIPT
  • 4.3 NIPT Approach
  • 4.4 Different Methods of NIPT
  • 4.5 Benefits and Risks Associated with NIPT
  • 4.6 Chromosomal Aneuploidy
  • 4.7 Features and Incidence Rate of Major Chromosomal Aneuploidies
  • 4.8 Technological Advancements
  • 4.9 World Economic Outlook of Non-Invasive Prenatal Testing Market, 2019
  • 4.1 Global Footprint

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Impact Analysis
  • 5.3 Market Drivers
    • 5.3.1 Increased Emphasis on Early Detection and Prevention
    • 5.3.2 Availability of Advanced Screening Technologies
    • 5.3.3 Increasing Consumer Demand
    • 5.3.4 Shifting of Reimbursement Policies Toward More Genetics Coverage
    • 5.3.5 High Incidence Rate of Down's Syndrome
    • 5.3.6 Rising Average Maternal Age
    • 5.3.7 Increasing Prevalence of Genetic and Congenital Disorders
  • 5.4 Market Restraints
    • 5.4.1 Stringent Regulatory Guidelines and Ethical Hurdles
    • 5.4.2 Limitations of NIPT
    • 5.4.3 Lack of Awareness Among Consumers
    • 5.4.4 Alternative Screening and Testing Methods
  • 5.5 Market Opportunities
    • 5.5.1 Capitalizing on the Potential Presented by the Emerging Markets in Asia
    • 5.5.2 Availability of Direct-to-Consumer Tests
    • 5.5.3 Focus on Pre-Implantation Genetic Diagnosis

6 Industry Insights

  • 6.1 Regulatory Framework
    • 6.1.1 Regulatory Scenario in the U.S.
    • 6.1.2 Regulatory Scenario in Canada
    • 6.1.3 Regulatory Scenario in the U.K.
    • 6.1.4 Regulatory Scenario in Germany
    • 6.1.5 Regulatory Scenario in France
    • 6.1.6 Regulatory Scenario in Spain
    • 6.1.7 Regulatory Scenario in Italy
    • 6.1.8 Regulatory Scenario in the Netherlands
    • 6.1.9 Regulatory Scenario in China
    • 6.1.10 Regulatory Scenario in India
    • 6.1.11 Regulatory Scenario in Australia
    • 6.1.12 Regulatory Scenario in Japan
  • 6.2 Clinical Laboratory Improvement Amendments (CLIA) Program
    • 6.2.1 Regulatory Authorities Involved in CLIA Program
  • 6.3 Cost and Access
  • 6.4 Reimbursement Scenario
  • 6.5 Funding Scenario
  • 6.6 Supply Chain
  • 6.7 Impact of COVID-19 Outbreak on the Global NIPT Market

7 Competitive Landscape

  • 7.1 Overview
  • 7.2 Key Developments and Strategies
    • 7.2.1 New Offerings
    • 7.2.2 Partnerships and Alliances
    • 7.2.3 Product Approvals
    • 7.2.4 Business Expansions
    • 7.2.5 Merger and Acquisition Activities
    • 7.2.6 Others
  • 7.3 Market Share Analysis, by Company
  • 7.4 Growth Share Analysis (Opportunity Mapping)
    • 7.4.1 by Platform

8 Global NIPT Market (by Test), 2020-2031

  • 8.1 Overview
  • 8.2 Panorama and Vistara
  • 8.3 MaterniT GENOME, MaterniT 21 PLUS, and informaSeq
  • 8.4 Verifi and Verifi Plus Prenatal Tests
  • 8.5 Harmony Test
  • 8.6 NIFTY Test and NIFTY-Test Pro
  • 8.7 QNatal Advanced
  • 8.8 PrenaTest, GeneSafe, and PrenatalSAFE
  • 8.9 Bambni Test
  • 8.1 IONA and Sage
  • 8.11 Others

9 Global NIPT Market (by Method), 2020-2031

  • 9.1 Overview
  • 9.2 cfDNA
  • 9.3 FCMB

10 Global NIPT Market (by Platform), 2020-2031

  • 10.1 Overview
  • 10.2 Next-Generation Sequencing
  • 10.3 PCR
  • 10.4 Others

11 Global NIPT Market (by Application), 2020-2031

  • 11.1 Overview
  • 11.2 Trisomy Detection
  • 11.3 Microdeletion Detection
  • 11.4 Sex Chromosome Aneuploidy Detection
  • 11.5 Others

12 Global NIPT Market (by End User), 2020-2031

  • 12.1 Overview
  • 12.2 Hospital
  • 12.3 Clinics
  • 12.4 Diagnostic Labs
  • 12.5 Others

13 Global NIPT Market (by Region), 2020-2031

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 Overview
      • 13.2.1.1 By Value and Volume
      • 13.2.1.2 By Value and Volume (by Country)
      • 13.2.1.3 Pricing Analysis by Leading NIPT Test
    • 13.2.2 U.S.
      • 13.2.2.1 By Value
      • 13.2.2.2 By Volume
      • 13.2.2.3 Organizations Offering NIPT Test
      • 13.2.2.4 Market Share Analysis
      • 13.2.2.5 Pricing Analysis by Leading NIPT Test
    • 13.2.3 Canada
      • 13.2.3.1 By Value
      • 13.2.3.2 By Volume
      • 13.2.3.3 Organizations Offering NIPT Test
      • 13.2.3.4 Market Share Analysis
      • 13.2.3.5 Pricing Analysis by Leading NIPT Test
  • 13.3 Europe
    • 13.3.1 Overview
      • 13.3.1.1 By Value and Volume
      • 13.3.1.2 By Value and Volume (by Country)
      • 13.3.1.3 Pricing Analysis by Leading NIPT Test
    • 13.3.2 Germany
      • 13.3.2.1 By Value
      • 13.3.2.2 By Volume
      • 13.3.2.3 Organizations Offering NIPT Test
      • 13.3.2.4 Market Share Analysis
    • 13.3.3 France
      • 13.3.3.1 By Value
      • 13.3.3.2 By Volume
      • 13.3.3.3 Organizations Offering NIPT Test
      • 13.3.3.4 Market Share Analysis
    • 13.3.4 Italy
      • 13.3.4.1 By Value
      • 13.3.4.2 By Volume
      • 13.3.4.3 Organizations Offering NIPT Test
      • 13.3.4.4 Market Share Analysis
    • 13.3.5 U.K.
      • 13.3.5.1 By Value
      • 13.3.5.2 By Volume
      • 13.3.5.3 Organizations Offering NIPT Test
      • 13.3.5.4 Market Share Analysis
    • 13.3.6 Spain
      • 13.3.6.1 By Value
      • 13.3.6.2 By Volume
      • 13.3.6.3 Organizations Offering NIPT Test
      • 13.3.6.4 Market Share Analysis
    • 13.3.7 Russia
      • 13.3.7.1 By Value
      • 13.3.7.2 By Volume
      • 13.3.7.3 Organizations Offering NIPT Test
      • 13.3.7.4 Market Share Analysis
    • 13.3.8 Poland
      • 13.3.8.1 By Value
      • 13.3.8.2 By Volume
      • 13.3.8.3 Organizations Offering NIPT Test
      • 13.3.8.4 Market Share Analysis
    • 13.3.9 Netherlands
      • 13.3.9.1 By Value
      • 13.3.9.2 By Volume
      • 13.3.9.3 Organizations Offering NIPT Test
      • 13.3.9.4 Market Share Analysis
    • 13.3.10 Belgium
      • 13.3.10.1 By Value
      • 13.3.10.2 By Volume
      • 13.3.10.3 Organizations Offering NIPT Test
      • 13.3.10.4 Market Share Analysis
    • 13.3.11 Switzerland
      • 13.3.11.1 By Value
      • 13.3.11.2 By Volume
      • 13.3.11.3 Organizations Offering NIPT Test
      • 13.3.11.4 Market Share Analysis
    • 13.3.12 Denmark
      • 13.3.12.1 By Value
      • 13.3.12.2 By Volume
      • 13.3.12.3 Organizations Offering NIPT Test
      • 13.3.12.4 Market Share Analysis
    • 13.3.13 Sweden
      • 13.3.13.1 By Value
      • 13.3.13.2 By Volume
      • 13.3.13.3 Organizations Offering NIPT Test
      • 13.3.13.4 Market Share Analysis
    • 13.3.14 Rest-of-Europe
      • 13.3.14.1 By Value
      • 13.3.14.2 By Volume
  • 13.4 Asia-Pacific
    • 13.4.1 Overview
    • 13.4.1 China
      • 13.4.1.1 By Value
      • 13.4.1.2 By Volume
    • 13.4.2 Japan
      • 13.4.2.1 By Value
      • 13.4.2.2 By Volume
    • 13.4.3 India
      • 13.4.3.1 By Value
      • 13.4.3.2 By Volume
    • 13.4.4 Australia
      • 13.4.4.1 By Value
      • 13.4.4.2 By Volume
    • 13.4.5 South Korea
      • 13.4.5.1 By Value
      • 13.4.5.2 By Volume
    • 13.4.6 Hong Kong
      • 13.4.6.1 By Value
      • 13.4.6.2 By Volume
    • 13.4.7 Malaysia
      • 13.4.7.1 By Value
      • 13.4.7.2 By Volume
    • 13.4.8 Indonesia
      • 13.4.8.1 By Value
      • 13.4.8.2 By volume
    • 13.4.9 Vietnam
      • 13.4.9.1 By Value
      • 13.4.9.2 By Volume
    • 13.4.10 Thailand
      • 13.4.10.1 By Value
      • 13.4.10.2 By Volume
    • 13.4.11 Philippines
      • 13.4.11.1 By Value
      • 13.4.11.2 By Volume
    • 13.4.12 Rest-of-APAC
      • 13.4.12.1 By Value
      • 13.4.12.2 By Volume
  • 13.5 Latin America
    • 13.5.1 By Value
    • 13.5.2 By Volume
  • 13.6 Rest-of-the-World
    • 13.6.1 By Value
    • 13.6.2 By Volume

14 Company Profiles

  • 14.1 Overview
  • 14.2 Agilent Technologies, Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Agilent Technologies, Inc. in the Global NIPT Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights About Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 F. Hoffmann-La Roche Ltd
    • 14.3.1 Company Overview
    • 14.3.2 Role of F. Hoffmann-La Roche Ltd in the Global NIPT Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights About Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 PerkinElmer, Inc.
    • 14.4.1 Company Overview
    • 14.4.2 Role of PerkinElmer, Inc. in the Global NIPT Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 Quest Diagnostics Incorporated
    • 14.5.1 Company Overview
    • 14.5.2 Role of Quest Diagnostics Incorporated in the Global NIPT Market
    • 14.5.3 Financials
    • 14.5.4 SWOT Analysis
  • 14.6 Illumina, Inc.
    • 14.6.1 Company Overview
    • 14.6.2 Role of Illumina, Inc. in the Global NIPT Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 Myriad Genetics, Inc.
    • 14.7.1 Company Overview
    • 14.7.2 Role of Myriad Genetics, Inc. in the NIPT Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 BGI
    • 14.8.1 Company Overview
    • 14.8.2 Role of BGI in the NIPT Market
    • 14.8.3 SWOT Analysis
  • 14.9 CENTOGENE N.V.
    • 14.9.1 Company Overview
    • 14.9.2 Role of CENTOGENE N.V. in the NIPT Market
    • 14.9.3 Financials
    • 14.9.4 Key Insights About Financial Health of the Company
    • 14.9.5 SWOT Analysis
  • 14.1 Laboratory Corporation of America Holdings
    • 14.10.1 Company Overview
    • 14.10.2 Role of Laboratory Corporation of America Holdings in the NIPT Market
    • 14.10.3 Financials
    • 14.10.4 SWOT Analysis
  • 14.11 MedGenome Inc.
    • 14.11.1 Company Overview
    • 14.11.2 Role of MedGenome Inc. in the Global NIPT Market
    • 14.11.3 SWOT Analysis
  • 14.12 Annoroad Gene Technology
    • 14.12.1 Company Overview
    • 14.12.2 Role of Annoroad Gene Technology in the NIPT Market
    • 14.12.3 SWOT Analysis
  • 14.13 Natera, Inc.
    • 14.13.1 Company Overview
    • 14.13.2 Role of Natera, Inc. in the Global NIPT Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights About Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 Yourgene Health PLC
    • 14.14.1 Company Overview
    • 14.14.2 Role of Yourgene Health PLC in the NIPT Market
    • 14.14.3 Financials
    • 14.14.4 SWOT Analysis
  • 14.15 Next Biosciences
    • 14.15.1 Company Overview
    • 14.15.2 Role of Next Biosciences in the NIPT Market
    • 14.15.3 SWOT Analysis
  • 14.16 Eurofins Scientific
    • 14.16.1 Company Overview
    • 14.16.2 Role of Eurofins Scientific in the NIPT Market
    • 14.16.3 Financials
    • 14.16.4 SWOT Analysis
Back to Top
전화 문의
F A Q